Following a review of disabling and potentially long-lasting side effects associated with fluoroquinolone and quinolone antibiotics, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) Friday recommended that all drugs containing a quinolone antibiotic be removed from the market. Such drugs are authorized only for infections that should no longer be treated with this class of antibiotics, PRAC said.